Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:Vloga imunskega sistema in imunoterapije pri trojno negativnem raku dojk
Authors:ID Grašič-Kuhar, Cvetka (Author)
Files:.pdf PDF - Presentation file, download (173,87 KB)
MD5: 0D3FB7F33827417E6EA71419C2D1655B
 
Language:Slovenian
Typology:1.02 - Review Article
Organization:Logo OI - Institute of Oncology
Abstract:Interakcija med tumorskimi celicami in imunskimi celicami tumorski stromi je pomembna za nastanek, razvoj in napredovanje raka. Pri raku dojk je najbolj preučena vloga tumorskega limfocitnega infiltrata (TIL) in izraženosti liganda za programirano smrt-1 (PD-L1). Večja izraženost TIL je neodvisni napovedni dejavnik za popolno patološko remisijo po neoadjuvantni sistemski terapiji pri HER2+ in trojno negativnem podtipu raka dojk ter za celotno preživetje pri trojno negativnem raku dojk. Največ raziskav z zaviralniki kontrolnih točk (imunoterapijo) poteka pri trojno negativnem metastatskem raku dojk. V klinični praksi se že uporablja atezolizumab v kombinaciji z nabpaklitakselom pri primarno metastatskih bolnicah in tistih s progresom več kot 12 mesecev po adjuvantni terapiji, če imajo čezmerno izražen PD-L1. Še vedno pa se raziskuje, kateri mehanizmi in biomarkerji so udeleženi pri odzivu imunskega sistema na tumor, saj ima le majhen delež bolnikov dolgotrajno dobrobit od imunoterapije.
Keywords:rak dojke, imunski sistem, imunoterapija, trojno negativni rak dojk
Publication status:Published
Publication version:Version of Record
Year of publishing:2020
Number of pages:str. 32-38
Numbering:Letn. 24, št. 1
PID:20.500.12556/DiRROS-12403 New window
UDC:618.1
ISSN on article:1408-1741
DOI:10.25670/oi2020-006on New window
COBISS.SI-ID:24701699 New window
Copyright:by Authors
Publication date in DiRROS:09.09.2020
Views:2926
Downloads:736
Metadata:XML DC-XML DC-RDF
:
GRAŠIČ-KUHAR, Cvetka, 2020, Vloga imunskega sistema in imunoterapije pri trojno negativnem raku dojk. Onkologija [online]. 2020. Vol. 24, no. 1, p. 32–38. [Accessed 26 March 2025]. DOI 10.25670/oi2020-006on. Retrieved from: https://dirros.openscience.si/IzpisGradiva.php?lang=eng&id=12403
Copy citation
  
Share:Bookmark and Share



Similar works from other repositories:

No similar works found

Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Onkologija
Shortened title:Onkologija
Publisher:Onkološki inštitut
ISSN:1408-1741
COBISS.SI-ID:65324032 New window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:01.06.2020

Secondary language

Language:English
Title:The role of the immune system in triple-negative breast cancer
Abstract:The interaction between tumour and immune cells in tumour stroma is very important for the formation, development and progression of cancer. The most evaluated interactions are tumour lymphocyte infiltration (TIL) and programmed death ligand 1 (PD-L1) expression. Higher TIL density is an independent prognostic factor for the achievement of complete pathologic remission (pCR) after neoadjuvant systemic treatment in HER2-positive and triple-negative breast cancer. In triple-negative breast cancer, TIL is also prognostic for overall survival. Many studies with immunotherapy (checkpoint inhibitors) are ongoing in triple-negative breast cancer. In routine clinical practice, patients can be treated with atezolizumab+Nab-paclitaxel in primary metastatic breast cancer and those with progression after more than 12 months after the end of adjuvant treatment, if their tumours express PD-L1. Many studies addressing the mechanisms of the immune system and biomarkers are ongoing to reveal why only a subset of patients profit from immunotherapy.


Archive

niGradiv

Back